Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Alprazolam
Drug ID BADD_D00085
Description Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.[L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.[L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down a patient's dose to avoid withdrawal symptoms.[A18125] Alprazolam's adverse effects are generally related to the sedation it can cause.[A18125] Alprazolam has been mixed with alcohol as a drug of abuse to potentiate the sedative effects of the drug which may lead to coma and death.[A18125] Alprazolam was given FDA approval on October 16, 1981.[L6148]
Indications and Usage For the management of anxiety disorder or the short-term relief of symptoms of anxiety and for the treatment of panic disorder, with or without agoraphobia.
Marketing Status Prescription; Discontinued
ATC Code N05BA12
DrugBank ID DB00404
KEGG ID D00225
MeSH ID D000525
PubChem ID 2118
TTD Drug ID D0L9GG
NDC Product Code 71335-1092; 12828-0040; 72189-029; 70954-511; 71335-1576; 0781-1061; 71335-1386; 53002-3950; 61919-836; 0009-0094; 65862-676; 53002-0340; 60760-550; 0228-4019; 72789-024; 0228-3086; 68071-4855; 50090-5257; 72789-087; 72189-058; 50090-5262; 0228-2039; 65862-677; 70954-510; 53002-4181; 68071-5243; 0615-8216; 68788-7594; 80425-0100; 63629-7726; 65162-812; 65862-456; 71335-1669; 61919-379; 71335-0849; 0228-2027; 72789-151; 55154-5885; 65862-679; 50090-5258; 72189-213; 65162-813; 55700-671; 50090-1759; 72189-240; 57218-312; 72789-042; 0228-2029; 71335-1894; 0781-1089; 71335-1839; 71335-1291; 71610-113; 45865-424; 70954-508; 61919-005; 71205-284; 68071-4818; 51991-705; 71335-0920; 65162-810; 80425-0110; 50090-5078; 59762-3721; 63187-971; 68788-7595; 51991-707; 72189-121; 0009-0066; 53002-3952; 64980-398; 59762-0059; 66267-564; 71335-1477; 42816-0090; 67296-0958; 65862-678; 53002-4180; 0228-3083; 0904-5860; 63187-518; 45865-993; 65862-455; 0054-3068; 65862-457; 60429-504; 68788-7596; 67544-347; 63629-8164; 0009-0057; 50090-4950; 61919-849; 49999-032; 64980-399; 0228-4024; 0228-2031; 70934-558; 63629-8172; 67544-414; 71205-614; 49884-214; 55289-523; 68071-4621; 0009-5144; 71335-1129; 63187-445; 65862-454; 59762-0066; 80425-0161; 71205-386; 68788-9682; 68071-4652; 70934-815; 51991-706; 0009-0068; 70518-3259; 59762-3719; 43063-609; 80425-0099; 0228-3084; 0228-4025; 59762-3720; 61919-576; 0009-0055; 68071-2236; 63629-8214; 12780-4630; 64980-396; 67253-901; 0781-1077; 67253-902; 64980-397; 68071-4923; 68071-5263; 71335-0813; 71205-227; 50090-5109; 42816-0029; 49999-252; 71610-112; 49884-110; 71335-0680; 63187-443; 0228-3087; 65162-809; 67253-900; 63187-225; 71554-013; 67253-903; 71205-290; 70518-2870; 55700-929; 35356-744; 65015-634; 0781-1079; 59762-0057; 71205-652; 59762-0068; 42816-0055; 0009-0029; 51991-704; 45865-972; 68071-5128; 68071-2220; 0009-0090; 63187-916; 67296-1748; 49452-0295; 71335-0673; 49884-213; 68071-4831; 63187-966; 0009-0059; 50090-5261; 63187-444; 50090-2781; 55700-312; 71335-1907; 59762-3722; 70954-509; 64330-013; 71335-0427; 0228-4022; 68788-7613; 68071-5113; 67544-415; 70518-2785; 0615-8295; 51655-266; 49884-111
Synonyms Alprazolam | Alprazolan | Trankimazin | U-31,889 | U31,889 | Xanax | Alprox | Esparon | Cassadan | D-65MT | D65MT | Kalma | Novo-Alprazol | Novo Alprazol | Nu-Alpraz | Nu Alpraz | Ralozam | Tafil | Apo-Alpraz | Apo Alpraz
Chemical Information
Molecular Formula C17H13ClN4
CAS Registry Number 28981-97-7
SMILES CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Anterograde amnesiaTranslocator proteinP30536T754409467187; 12798263; 9500121; 10803407; 9698157; 1668111; 14723318; 11968060
Anterograde amnesiaPlatelet-activating factor receptorP25105T870239467187; 12798263; 9500121; 10803407; 9698157; 1668111; 14723318; 11968060
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dysmenorrhoea21.01.01.002--
Dyspepsia07.01.02.001--
Dysphagia07.01.06.003--
Dysphonia22.02.05.005; 19.19.03.002; 17.02.08.004--
Dysphoria19.04.02.004--Not Available
Dyspnoea22.02.01.004; 02.01.03.002--
Dyspnoea exertional22.02.01.005; 02.01.03.003--Not Available
Dystonia17.01.03.001--Not Available
Dysuria20.02.02.002--
Ear disorder04.03.01.001--Not Available
Ear pain04.03.01.003--
Eczema23.03.04.006--
Electrocardiogram abnormal13.14.05.0010.000125%Not Available
Electrocardiogram QRS complex prolonged13.14.05.003--Not Available
Electrocardiogram QT prolonged13.14.05.0040.001003%
Electroencephalogram abnormal13.07.03.0010.000084%Not Available
Emotional disorder19.04.02.005--Not Available
Encephalopathy17.13.02.001--
Eosinophil count13.01.06.021--Not Available
Eosinophilia01.02.04.0010.000502%
Epilepsy17.12.03.0020.000878%Not Available
Epistaxis24.07.01.005; 22.04.03.001--
Erythema23.03.06.001--Not Available
Erythema multiforme10.01.03.015; 23.03.01.003--
Euphoric mood19.04.02.0060.000293%
Extrapyramidal disorder17.01.02.0070.000418%
Extrasystoles02.03.02.0030.000084%Not Available
Eye disorder06.08.03.001--Not Available
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.003--
Faeces discoloured07.01.03.002--Not Available
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 25 Pages